Normally when you put out a product, you want to take sales away from the competition, not from other products that you sell yourself. But that's exactly what Gilead Sciences (NASDAQ:GILD) is doing, and Motley Fool health care analyst David Williamson thinks it's a great move. Watch the video to find out why.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Gilead: Biotech's Smartest Cannibal
By Dave Williamson and Max Macaluso
–
Nov 15, 2012 at 2:52PM
NASDAQ: GILD
Gilead Sciences
Market Cap
$105B
Today's Change
(-0.19%) -$0.16
Current Price
$84.43
Price as of October 7, 2024, 4:00 p.m. ET
Switching patients to a new drug of your own may not be a bad thing.
David Williamson owns shares of Johnson & Johnson. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Motley Fool newsletter services recommend Gilead Sciences and Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.